Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cryoseal fibrin sealant shows promise in TKA (total knee arthroplasty):

This article was originally published in Clinica

Executive Summary

ThermoGenesis says that an early study has produced evidence to support the use of its CryoSeal autologous fibrin sealant in total knee arthroplasty (TKA). The 21-patient pilot trial showed that total blood loss in TKA was reduced by 50% when using the sealant. The CryoSeal patients also had better cardiovascular stability, a higher range of motion, less pain and better wound healing than the control group. Plans are underway to confirm the results in a larger study. It has been estimated that over 1.3 million TKA procedures are performed annually worldwide, says the Rancho Cordova, California firm. The CryoSeal FS system is CE-marked for sale in Europe.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054149

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel